NovelStem International Corp. Exits Active Biotech Operations, Retains Contingent Rights on Stem Cell Technology License
After liquidating its biotech subsidiary and divesting media assets, NovelStem’s current value hinges on uncertain future licensing revenues from stem cell-based technology.
NovelStem International Corp., originally a media business and since 2018 a biotechnology holding company, underwent significant structural changes following the liquidation of its Israeli biotech subsidiary NewStem Ltd in late 2025. The sale of its joint venture interest in NetCo Partners closed earlier in 2025, leaving NovelStem with no direct operational subsidiaries. Its core remaining asset is a financial interest in potential future monetization of an exclusive stem cell technology license held by Yissum Research Development Company. Despite reporting a net income in 2025, the company continues to face severe liquidity challenges and lacks current revenue streams. Realizing value from its retained license rights remains a key uncertainty amid continuing financial constraints and regulatory risks.
Company Background and Transition
NovelStem International Corp., formerly Hollywood Media Corp., transformed its strategic direction in 2018 by acquiring NewStem Ltd., an Israeli biotechnology firm pioneering haploid human pluripotent stem cell (hPSC) technology. This marked a shift from legacy media operations towards an innovative biotech platform targeting cancer diagnostics and therapeutics [S1],[S27].
Initially holding approximately a 31% equity stake in NewStem and a 50% interest in NetCo Partners (owner of an entertainment franchise), NovelStem exerted significant influence over NewStem operations through leadership roles held by its Executive Chairman Jan Loeb [S1]. However, the company never consummated a full acquisition agreement intended for mid-2024 due to funding failures [S1].
Historical Performance and Drivers
NovelStem’s reported revenue has been minimal since transitioning focus; the last meaningful revenue point dates back several years with $616k recorded at the end of 2012 [F1]. Following the pivot to biotech, reported top-line revenues effectively dropped off as research and development efforts predominated.
Operating losses narrowed substantially from approximately -$928k in 2024 to -$239k in 2025 [F1], reflecting cost reductions alongside non-operating gains. Notably, net income swung positive to about $2.38 million in 2025 compared to a loss of over $3.23 million the prior year due largely to one-time noncash gains from asset sales and debt settlements rather than operating profitability [F1],[S3],[S21].
Cash flow from operations remained negative at approximately -$168k for 2025 despite these accounting gains [F1], highlighting ongoing consumption of liquidity in day-to-day activities.
Historical performance (annual)
| FY | Net ($mm) | CFO ($) | OpInc ($mm) | Net YoY |
|---|---|---|---|---|
| 2025 | 2 | -167633 | 0 | +173.6% |
| 2024 | -3 | -271964 | -1 | +22.8% |
| 2023 | -4 | -348283 | -4 | -446.8% |
| 2022 | -1 | -182320 | 0 |
Source: SEC companyfacts cache [F1].
Capital returns and efficiency (annual)
| FY | ROE% |
|---|---|
| 2025 | -111.1 |
| 2024 | 62.8 |
| 2023 | 214.6 |
| 2022 | -39.6 |
Source: SEC companyfacts cache [F1].
*Note: Revenues are negligible or absent post-transition. Net income improvement primarily from one-off items not recurring operations.
Asset Base Changes and Strategic Moves
During H1-2025 NovelStem divested its entire interest in NetCo Partners for $1.3 million — a transaction that settled longstanding litigation funding obligations with Omni Bridgeway [S3],[S21]. This divestiture ended NovelStem’s legacy media exposure.
Meanwhile, NewStem ceased operations and entered liquidation in October 2025 after failing to secure necessary financing or meet operational goals [S1],[S23]. The core intellectual property — based on exclusive licensing arrangements with Yissum Research Development Company — reverted entirely to Yissum. NovelStem now holds only contingent financial rights tied to future monetization of this license estimated up to $3.75 million but without direct control or guaranteed realization [S1],[S23].
Current Financial Condition and Capital Structure
As of December 31, 2025:
- Current assets stood at approximately $15,786.
- Current liabilities remained elevated around $2.16 million.
- Total shareholders' deficit approximated $(2.14) million reflecting ongoing accumulated losses ([F1],[S4],[S10]).
The company relies heavily on related party financing including bridge loans advanced by Executive Chairman Jan Loeb totaling $161k during the year bearing interest at about 10%, with maturities extended into mid-2026 [S3],[S8],[S13].
Convertible notes with unrelated parties account for additional debt exposure bearing similar rates and maturity extensions [S9],[S13]. Debt agreements include provisions granting note holders participation rights in any equity capital raise at enhanced multiples relative to amounts owed [S3],[S14].
Operational cash burn necessitates continued external financing or successful license monetization for viability beyond the next year [S14],[S20].
Future Growth Prospects and Outlook
Following NewStem’s liquidation and NetCo exit, NovelStem’s prospects depend predominantly on:
- Successful commercialization or licensing of the exclusive haploid stem cell technology currently controlled by Yissum.
- Monetization agreements entitling NovelStem up to $3.75 million contingent on license exploitation outcomes; however, realization remains highly uncertain with no timelines provided.
- Ability to secure sustainable funding to cover operating costs until such monetization occurs given limited cash reserves and high leverage.
Regulatory hurdles pose significant risk given that NewStem’s diagnostic device received European CE Mark approval but never achieved FDA clearance—a critical barrier for accessing large U.S. markets [S27]. The broader stem cell biotech sector is subject to rapid technological advances which could impact competitive advantage unless active R&D continues via new licensees or partners.
Returns / Capital Allocation History
Since shifting focus post-2018 transformation, NovelStem has not declared dividends nor engaged in share repurchases ([F1]). Accumulated deficits since inception exceed $294 million reflecting development stage biotech investments prior to NewStem's liquidation [S1].[F1]
Approximate return on equity for latest fiscal year is negative (~-111%), driven by net income improvements from accounting adjustments but offset by a deeply negative equity base ([F1]).
Free cash flow remains negative at roughly -$252k combining operating cash outflows with minimal capital expenditures as substantive R&D has ceased following NewStem dissolution ([F1]).
Risk Factors Summary
Principal risks facing NovelStem include:
- Heavy reliance on speculative future monetization of intellectual property without direct operational control.
- Thin liquidity position coupled with high current liabilities demanding near-term refinancing or cash inflows.
- Regulatory uncertainty surrounding commercialization possibility especially absent FDA-approved products.
- Technological obsolescence risks given rapid advancement dynamics within stem cell medical research sectors.
- Material weaknesses noted during financial audits impacting reliability of disclosures and oversight capabilities [S24],[S26].
Conclusion
NovelStem International Corp.'s evolution into a biotechnology holding company culminated recently with exit from active operations following NewStem Ltd's liquidation and sale of joint venture media interests. With core proprietary assets reverted back to original licensors but retaining contingent revenue rights on possible future licensing efforts via Yissum Research Development Company, NovelStem presently exists as an entity with uncertain prospects dependent largely on intangible asset monetization outcomes yet unrealized. Meanwhile liquidity constraints force dependence on shareholder loans while operating losses persist absent recurring revenue streams. Vigilance around its ability to generate licensing proceeds or secure additional capital will be crucial going forward.
Disclaimer: This report is prepared solely for informational purposes based on publicly available filings and does not constitute investment advice or recommendations regarding NovelStem International Corp.
Disclaimer: This is research-only, informational analysis and not investment advice. It may include AI-generated interpretation and general industry context. Always verify important details using primary sources.
Comments